PubRank

Brian B Hasinoff

Author PubWeight™ 27.41‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Expression of a stress-induced hemoglobin affects NO levels produced by alfalfa root cultures under hypoxic stress. Plant J 2003 1.49
2 Class-1 hemoglobins, nitrate and NO levels in anoxic maize cell-suspension cultures. Planta 2004 1.08
3 Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology 2008 1.07
4 Arrest of B16 melanoma cells in the mouse pulmonary microcirculation induces endothelial nitric oxide synthase-dependent nitric oxide release that is cytotoxic to the tumor cells. Am J Pathol 2003 1.01
5 Mechanism of the cytotoxicity of the diazoparaquinone antitumor antibiotic kinamycin F. Free Radic Biol Med 2007 0.96
6 A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors. Mol Pharmacol 2007 0.92
7 A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone. J Chem Inf Model 2006 0.91
8 Cell lysis with dimethyl sulphoxide produces stable homogeneous solutions in the dichlorofluorescein oxidative stress assay. Free Radic Res 2008 0.90
9 Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radic Biol Med 2002 0.88
10 Development of a nitric oxide-releasing analogue of the muscle relaxant guaifenesin for skeletal muscle satellite cell myogenesis. Mol Pharm 2009 0.88
11 Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents. Bioorg Med Chem 2010 0.87
12 Kinamycin F downregulates cyclin D3 in human leukemia K562 cells. Chem Biol Interact 2010 0.85
13 A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II. Bioorg Med Chem 2009 0.83
14 Design, synthesis, and biological evaluation of a novel series of bisintercalating DNA-binding piperazine-linked bisanthrapyrazole compounds as anticancer agents. Bioorg Med Chem 2011 0.82
15 Thiol-modulated mechanisms of the cytotoxicity of thimerosal and inhibition of DNA topoisomerase II alpha. Chem Res Toxicol 2008 0.82
16 Evaluation of relative DNA binding affinities of anthrapyrazoles by electrospray ionization mass spectrometry. J Mass Spectrom 2007 0.81
17 A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs. Mol Pharmacol 2006 0.81
18 Total synthesis of isoprekinamycin: structural evidence for enhanced diazonium ion character and growth inhibitory activity toward cancer cells. Org Lett 2007 0.79
19 The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species. Anticancer Drugs 2005 0.79
20 Role of NADPH cytochrome P450 reductase in activation of RH1. Cancer Chemother Pharmacol 2007 0.79
21 The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα. Biochem Pharmacol 2012 0.79
22 The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925. Cancer Chemother Pharmacol 2002 0.78
23 Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187). Drug Metab Dispos 2002 0.78
24 Prevention of doxorubicin-induced damage to rat heart myocytes by arginine analog nitric oxide synthase inhibitors and their enantiomers. Nitric Oxide 2003 0.77
25 Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat. Drug Metab Dispos 2005 0.77
26 Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide. Cancer Chemother Pharmacol 2003 0.77
27 The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites. Drug Metab Dispos 2008 0.77
28 Molecular mechanisms of the biological activity of the anticancer drug elesclomol and its complexes with Cu(II), Ni(II) and Pt(II). J Inorg Biochem 2013 0.76
29 Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent. Cancer Chemother Pharmacol 2003 0.76
30 The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin. J Inorg Biochem 2004 0.76
31 Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood. Drug Metab Dispos 2005 0.75
32 Cadmium is a catalytic inhibitor of DNA topoisomerase II. J Inorg Biochem 2011 0.75
33 Structure-activity studies with cytotoxic anthrapyrazoles. Oncol Rep 2006 0.75
34 Chemical reactivity and microbicidal action of bethoxazin. Bioorg Med Chem 2012 0.75